Radical radiotherapy with or without gemcitabine in patients with early stage medically inoperable non-small cell lung cancer

No evidence of an improvement in event-free survival was seen with the addition of weekly gemcitabine at this dose for patients with early stage NSCLC unfit for surgery, although the power of the study was low.